Abstract
Carcinoma of the prostate is one of the most common cancers in men over 50 years of age and is the second leading cause of cancer death in men over 75. As a general rule, symptoms usually are not apparent until the tumor is far advanced. Between 80 to 90 percent of patients have metastatic disease at the time of presentation and are not curable by surgery. Endocrine manipulation remains the most effective and commonly used treatment for metastatic carcinoma of the prostate.
Subject
Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics
Reference49 articles.
1. Rubin P, ed. Clinical oncology for medical students and physicians—a multidisciplinary approach. 6th ed. Rochester, NY: American Cancer Society, 1983: 210–9.
2. Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.
3. Clemente CD, ed. Gray's anatomy. Philadelphia: WB Saunders, 1985: 1540.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献